DURHAM, N.C.--(BUSINESS WIRE)--Argos Therapeutics today announced the publication of an article in the peer-reviewed online journal PLoS ONE supporting the company’s novel approach to stimulating a patient-specific immune response to HIV infection. The present study describes the adaptation of Argos’ proprietary Arcelis™ technology platform to create a personalized immunotherapy product that is perfectly matched to each patient’s unique viral load. This approach overcomes the extreme patient-to-patient viral diversity that Argos researchers believe is a primary factor in the failure of other HIV immune-based therapies.
